Literature DB >> 12050354

Highly pathogenic simian immunodeficiency virus mne variants that emerge during the course of infection evolve enhanced infectivity and the ability to downregulate CD4 but not class I major histocompatibility complex antigens.

Parul G Patel1, Monica T Yu Kimata, Julia E Biggins, Joelle M Wilson, Jason T Kimata.   

Abstract

The replicative, cytopathic, and antigenic properties of simian immunodeficiency virus (SIV) variants influence its replication efficiency in vivo. To further define the viral properties and determinants that may be important for high-level replication in vivo and progression to AIDS, we compared a minimally pathogenic SIVmne molecular clone with two highly pathogenic variants cloned from late stages of infection. Both variants had evolved greater infectivity than the parental clone due to mutations in nef. Interestingly, a pol determinant in one of the highly pathogenic variants also contributed to its increased infectivity. Furthermore, because replication in vivo may also be influenced by the ability of a virus to evade the cellular immune response of the host, we examined whether the variants were more capable of downregulating surface expression of class I major histocompatibility complex (MHC). Decreased MHC class I expression was not observed in cells infected with any of the viruses. Furthermore, the Nef proteins of the highly pathogenic variants only slightly reduced surface MHC class I expression in transfected cells, although they efficiently downregulated CD4. Together, these data demonstrate that mutations which can enhance viral infectivity, as well as CD4 downregulation, may be important for efficient replication of SIV in the host. However, Nef-mediated reduction of MHC class I expression does not appear to be critical for the increased in vivo replicative ability of highly pathogenic late variants.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050354      PMCID: PMC136284          DOI: 10.1128/jvi.76.13.6425-6434.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.

Authors:  H Akari; S Arold; T Fukumori; T Okazaki; K Strebel; A Adachi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 2.  Interactions of HIV-1 NEF with cellular signal transducing proteins.

Authors:  G H Renkema; K Saksela
Journal:  Front Biosci       Date:  2000-02-01

3.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

4.  The biological phenotype of HIV-1 is usually retained during and after sexual transmission.

Authors:  J R Fiore; A Björndal; K A Peipke; M Di Stefano; G Angarano; G Pastore; H Gaines; E M Fenyö; J Albert
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

5.  Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.

Authors:  M Y Chowers; C A Spina; T J Kwoh; N J Fitch; D D Richman; J C Guatelli
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

6.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

7.  Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression.

Authors:  R I Connor; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages.

Authors:  S Swingler; A Mann; J Jacqué; B Brichacek; V G Sasseville; K Williams; A A Lackner; E N Janoff; R Wang; D Fisher; M Stevenson
Journal:  Nat Med       Date:  1999-09       Impact factor: 87.241

10.  The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes.

Authors:  C A Spina; T J Kwoh; M Y Chowers; J C Guatelli; D D Richman
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  18 in total

1.  Counteraction of HLA-C-mediated immune control of HIV-1 by Nef.

Authors:  Anke Specht; Amalio Telenti; Raquel Martinez; Jacques Fellay; Elizabeth Bailes; David T Evans; Mary Carrington; Beatrice H Hahn; David B Goldstein; Frank Kirchhoff
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

2.  Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes.

Authors:  Miranda Z Smith; C Jane Dale; Robert De Rose; Ivan Stratov; Caroline S Fernandez; Andrew G Brooks; Jason Weinfurter; Kendall Krebs; Cara Riek; David I Watkins; David H O'connor; Stephen J Kent
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.

Authors:  Rajesh Thippeshappa; Patricia Polacino; Monica T Yu Kimata; Edward B Siwak; David Anderson; Weiming Wang; Laura Sherwood; Reetakshi Arora; Michael Wen; Paul Zhou; Shiu-Lok Hu; Jason T Kimata
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

4.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

5.  Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection.

Authors:  Steffen Wildum; Michael Schindler; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  Simian immunodeficiency virus variants that differ in pathogenicity differ in fitness under rapid cell turnover conditions.

Authors:  Yegor Voronin; Julie Overbaugh; Michael Emerman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles.

Authors:  Michael Schindler; Stephanie Würfl; Philippe Benaroch; Thomas C Greenough; Rod Daniels; Philippa Easterbrook; Matthias Brenner; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation.

Authors:  Tasha Biesinger; Robert White; Monica T Yu Kimata; Brenda K Wilson; Jonathan S Allan; Jason T Kimata
Journal:  Retrovirology       Date:  2010-10-13       Impact factor: 4.602

9.  Nef proteins from simian immunodeficiency virus-infected chimpanzees interact with p21-activated kinase 2 and modulate cell surface expression of various human receptors.

Authors:  Frank Kirchhoff; Michael Schindler; Nicola Bailer; G Herma Renkema; Kalle Saksela; Volker Knoop; Michaela C Müller-Trutwin; Mario L Santiago; Frederic Bibollet-Ruche; Matthias T Dittmar; Jonathan L Heeney; Beatrice H Hahn; Jan Münch
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.

Authors:  Michael S Mitchell; Ellen T Bodine; Shawn Hill; Gerald Princler; Patricia Lloyd; Hiroaki Mitsuya; Masao Matsuoka; David Derse
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.